Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
First Claim
Patent Images
1. An avidin dimer, in which two molecules of avidin are bound via the —
- NH2 groups by crosslinking with disuccinimidyl suberate.
0 Assignments
0 Petitions
Accused Products
Abstract
Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.
-
Citations
32 Claims
-
1. An avidin dimer, in which two molecules of avidin are bound via the —
- NH2 groups by crosslinking with disuccinimidyl suberate.
- View Dependent Claims (3, 5, 7, 9, 10, 11, 15, 17, 19, 21, 22, 23, 27, 29, 31)
-
2. An avidin dimer, in which two molecules of avidin are bound via the —
- COOH groups by crosslinking with polyethylene glycol diamine with a molecular weight of 3400.
- View Dependent Claims (4, 6, 8, 12, 13, 14, 16, 18, 20, 24, 25, 26, 28, 30, 32)
Specification